Pratima Chowdary, MD

Consultant Haematologist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom

Prof. Pratima Chowdary, MD, FRCPath, Centre Director for the Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital and Professor of Haemophilia and Haemostasis, Dept. of Haematology, University College of London (UCL)

Dr Chowdary is a consultant haematologist for more than 15 years and is the current Chairperson for the United Kingdom Haemophilia Centre Doctors Organisation and serves as co-director for the National Haemophilia Database. She had completed her medical training at Osmania University, India and NTR Health University, India, followed by subspecialty training in Hematology in London.

Dr Chowdary’s research interests lie in improving strategies and clinical outcomes for personalized management of haemophilia, with a focus on novel assays for bleeding diathesis and thrombotic tendency. Dr Chowdary has served as the chief investigator for a number of clinical trials, elucidating the hemostatic and musculoskeletal outcomes of gene therapy and other novel treatments for severe haemophilia. She has overseen the development of a biobank at the Royal Free Hospital and in addition to running several investigator-initiated studies.

She has authored more than 100 peer-reviewed publications, including three textbook chapters. She has contributed in various different roles to national and international working parties, data safety monitoring boards, trial steering committees, and national research peer review panels. She is also a member of numerous professional societies, including the International Society on Thrombosis and Haemostasis, British Society of Haemostasis and Thrombosis, European Association of Allied Bleeding disorders and the World Federation of Haemophilia.

Presentation(s):

• LB 01.4 - Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• PB0045 - A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: the PACA trial

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0082 - Biomarkers in COVID-19: Association with disease severity and outcomes

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0213 - Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients with Hemophilia B

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 30.1 - Emicizumab prophylaxis in people with severe haemophilia A without inhibitors: outcomes from the UK Haemophilia Centre Doctors' Organisation

  Monday, July 11, 2022
  10:45 AM – 11:00 AM

• OC 30.5 - Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

  Monday, July 11, 2022
  11:45 AM – 12:00 PM

• SS 17.6 - Factors to Consider: Expert Perspectives on Haemophilia A

  Monday, July 11, 2022
  1:15 PM – 2:30 PM

• SS 17.1 - Welcome

  Monday, July 11, 2022
  1:15 PM – 1:25 PM

• SS 17.5 - Closing

  Monday, July 11, 2022
  2:25 PM – 2:30 PM

• OC 40.6 - Non-Replacement Therapies II

  Monday, July 11, 2022
  2:45 PM – 4:00 PM

• OC 40.1 - FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy

  Monday, July 11, 2022
  2:45 PM – 3:00 PM

• OC 50.5 - Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors

  Tuesday, July 12, 2022
  11:45 AM – 12:00 PM